{
  "source": "PA-Notification-Praluent.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1166-12\nProgram Prior Authorization/Notification\nMedication Praluent® (alirocumab)*\nP&T Approval Date 8/2015, 7/2016, 7/2017, 7/2018, 7/2019, 7/2020, 6/2021, 6/2022, 6/2023,\n2/2024, 5/2024, 5/2025\nEffective Date 8/1/2025\n1. Background:\nPraluent (alirocumab) is a PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) inhibitor\nantibody indicated:\n• To reduce the risk of myocardial infarction, stroke, and unstable angina requiring\nhospitalization in adults with established cardiovascular disease.\n• As adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol\n(LDL-C)-lowering therapies (e.g., statins, ezetimibe), for the treatment of adults with primary\nhyperlipidemia (including heterozygous familial hypercholesterolemia) to reduce LDL-C.\n• As an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial\nhypercholesterolemia (HoFH) to reduce LDL-C.\n• As an adjunct to diet and other LDL-C-lowering therapies in pediatric patients aged 8 years\nand older with HeFH to reduce LDL-C.\n2. Coverage Criteriaa:\nA. Hyperlipidemia\n1. Initial Authorization\na. Praluent* will be approved based on all of the following criteria:\n(1) One of the following diagnoses:\n(a) Primary hyperlipidemia\n-OR-\n(b) Heterozygous familial hypercholesterolemia (HeFH)\n-OR-\n(c) Atherosclerotic cardiovascular disease (ASCVD) (e.g., acute coronary\nsyndromes, history of myocardial infarction, stable or unstable angina,\ncoronary or other arterial revascularization, stroke, transient ischemic attack, or\nperipheral arterial disease presumed to be of atherosclerotic origin)\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n1\n(2) Not used in combination with another proprotein convertase subtilisin/kexin type\n9 (PCSK9) inhibitor [e.g., Repatha (evolocumab)]\n-AND-\n(3) Not used in combination with Leqvio (inclisiran)\nAuthorization will be issued for 12 months\n2. Reauthorization\na. Praluent* will",
    "n/kexin type\n9 (PCSK9) inhibitor [e.g., Repatha (evolocumab)]\n-AND-\n(3) Not used in combination with Leqvio (inclisiran)\nAuthorization will be issued for 12 months\n2. Reauthorization\na. Praluent* will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Praluent* therapy\n-AND-\n(2) Not used in combination with another proprotein convertase subtilisin/kexin type\n9 (PCSK9) inhibitor [e.g., Repatha (evolocumab)]\n-AND-\n(3) Not used in combination with Leqvio (inclisiran)\nAuthorization will be issued for 12 months\nB. Homozygous Familial Hypercholesterolemia\n1. Initial Authorization\na. Praluent* will be approved based on all of the following criteria:\n(1) Diagnosis of homozygous familial hypercholesterolemia\n-AND-\n(2) Patient is receiving other lipid-lowering therapy (e.g., statin, ezetimibe, LDL\napheresis)\n-AND-\n(3) Not used in combination with another proprotein convertase subtilisin/kexin type 9\n(PCSK9) inhibitor [e.g., Repatha (evolocumab)]\n-AND-\n(4) Not used in combination with Juxtapid (lomitapide)\nAuthorization will be issued for 12 months\n© 2025 UnitedHealthcare Services, Inc.\n2\n2. Reauthorization\na. Praluent* will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Praluent* therapy\n-AND-\n(2) Not used in combination with another proprotein convertase subtilisin/kexin type 9\n(PCSK9) inhibitor\n-AND-\n(3) Not used in combination with Juxtapid (lomitapide)\nAuthorization will be issued for 12 months\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n*Praluent is typically excluded from coverage. Tried/Failed criteria may be in place. Please refer to\nplan specifics to determine exclusion status.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\n",
    "be in place. Please refer to\nplan specifics to determine exclusion status.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Medical Necessity, Supply Limits and Step Therapy may be in place.\n4. References:\n1. Praluent [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals; March 2024.\nProgram Prior Authorization/Notification – Praluent® (alirocumab)\nChange Control\n8/2015 New program.\n7/2016 Annual Review. Updated reference.\n7/2017 Annual review with no changes to coverage criteria. Updated reference.\n7/2018 Annual review with no changes to coverage criteria. Updated reference.\n7/2019 Annual review. Updated background and criteria aligning with new label\nfor the prevention of cardiovascular events in patients with established\nASCVD and in patients with primary hyperlipidemia alone or in\ncombination with other therapies. Updated reference.\n7/2020 Annual review with no changes to coverage intent. Changed initial\nauthorization to 12 months. Updated reference.\n6/2021 Annual review. Updated background and added criteria to align with new\nlabel for homozygous familial hypercholesterolemia. Added Praluent\nexclusion statement. Updated references.\n© 2025 UnitedHealthcare Services, Inc.\n3\n6/2022 Annual review with no changes to coverage criteria. Added state mandate\nfootnote and updated exclusion statement.\n6/2023 Annual review. Updated background. Added criteria that Praluent is not\nto be used in combination with Leqvio.\n2/2024 Simplified reauthorization criteria.\n5/2024 Updated background to align with new label for pediatric patients aged 8\nyears and older with HeFH. Updated reference.\n5/2025 Annual review. Removed diet requirement.\n© 2025 UnitedHealthcare Services, Inc.\n4"
  ]
}